Browse News
Filter News
Found 685 articles
-
A new report by PwC projects that the second half of this year will see a “flurry of deals activity across all areas of the sector.”
-
Inozyme Pharma Announces Partnership with Rady Children’s Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases
6/16/2022
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, announced a partnership with Rady Children’s Institute for Genomic Medicine to advance and evaluate a novel newborn screening technology to facilitate diagnosis of genetic diseases.
-
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPDTop-line data expected from ENHANCE-2 in Q3 2022 and ENHANCE-1 around the end of 2022
6/9/2022
Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has completed patient enrollment with more than 800 subjects randomized in the ENHANCE-1 trial, evaluating ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.
-
Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer
6/7/2022
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Kurt Gunter, M.D., as chief medical officer.
-
Verona Pharma to Host KOL Event on June 16, 2022
6/6/2022
Verona Pharma plc, announces it will host an in-person KOL event for analysts and investors on Thursday, June 16, 2022, at 8:00 AM ET, in New York.
-
Synthetic Biology Market Size to Surpass US$ 40.97 Billion by 2030
6/2/2022
According to Vision Research Reports, the Synthetic Biology market size is expected to surpass around US$ 40.97 billion by 2030 from valued at US$ 10.88 billion in 2020 and growing at a CAGR of 21.8% from 2021 to 2030.
-
Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference
6/1/2022
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will present at the Jefferies Healthcare Conference.
-
Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022
5/27/2022
Bolt Biotherapeutics, Inc. today announced that it will be presenting a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held at McCormick Place in Chicago and virtually from June 3-7, 2022.
-
Verona Pharma to Present at Jefferies Healthcare Conference - May 25, 2022
5/25/2022
Verona Pharma plc, announces that Chris Martin, Senior Vice President of Commercial, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:30 PM ET / 6:30 PM BST.
-
Synthetic Biology Market Size Reach US$ 40.97 billion by 2030
5/25/2022
The global Synthetic Biology market size is expected to be worth around US$ 40.97 billion by 2030, according to a new report by Vision Research Reports.
-
Transcat Reports Record Revenue and Adjusted Earnings Per Share for Fourth Quarter and Full Year Fiscal 2022
5/23/2022
Transcat, Inc. reported financial results for its fourth quarter and fiscal year ended March 26, 2022.
-
ReviR Therapeutics Announces Addition of Dr. Lynne E. Maquat and Dr. Brian Safina to Scientific Advisory Board
5/13/2022
ReviR Therapeutics announced the formation and members of its Scientific Advisory Board with the appointments of Dr. Lynne E. Maquat and Dr. Brian Safina.
-
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
5/12/2022
Bolt Biotherapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided an update on recent business highlights.
-
Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights
5/10/2022
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights.
-
Rare Inflammatory Disease Treatment Market Is Set to Experience a Significant Growth Of 4.6% CAGR From 2022 To 2028 - Comprehensive Research Report By FMI
5/10/2022
DUBAI, United Arab Emirates, Significant findings from report show that the global market for rare inflammatory disease treatment will increase at an assessed 4.6% CAGR during the forecast period, 2022-2028.
-
Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022
5/9/2022
Verona Pharma plc announces the presentation of an abstract demonstrating ensifentrine met all safety objectives in a through QT study at the American Thoracic Society International Conference 2022 taking place on May 13-18.
-
Artiva Biotherapeutics Appoints Edith A. Perez, M.D., to Its Board of Directors and Clinical Advisory Board
5/5/2022
Artiva Biotherapeutics, Inc. today announced the appointment of Edith A. Perez, M.D., as a member of the Company’s Board of Directors.
-
Verona Pharma Announces May 2022 Investor Conference Participation
5/4/2022
Verona Pharma plc, announces the company will participate in the following conferences in May 2022:
-
Synthetic Biology Market Size to Hit US$ 40.97 BN by 2030
5/4/2022
The global Synthetic Biology market size is expected to hit US$ 40.97 billion by 2030 and is projected to grow at a CAGR of 21.8% during forecast period 2021 to 2030.
-
Inozyme Pharma to Present at Upcoming Investor Conferences - May 03, 2022
5/3/2022
Inozyme Pharma, Inc. announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will present at the following investor conferences: